Kura Oncology KURA ROW License — Contract With Customer Liability Revenue Recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Kura Oncology in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.
The source filing: Kura Oncology’s 10-K, filed March 5, 2026.
- Filed
- Mar 5, 2026, 7:31 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-092567
For the years ended December 31, 2025 and 2024, we recognized $20.4 million and $49.8 million, respectively, of revenue allocated to the ROW License at a point in time. The allocated consideration related to the Development Services performance obligations is being recognized over time using a cost-to-cost measure of progress. We estimated the total cost expected to perform the required activities and measured the progress towards completion of each of these obligations at the reporting period. For the years ended December 31, 2025 and 2024, we recognized $28.0 million and $0.5 million of revenue from Development Services for monotherapy, respectively. For the years ended December 31, 2025 and 2024, we recognized $19.3 million and $0.8 million of revenue from Development Services in combination with other therapies, respectively. For the year ended December 31, 2025, we also recognized $0.5 million of revenue pursuant to services performed under the Kyowa Clinical Supply Agreement.
Item 16. Form 10-K Summary.
FAQ
- What is Kura Oncology's ROW license — contract with customer liability revenue recognized?
- Kura Oncology (KURA) reported ROW license — contract with customer liability revenue recognized of $5.1M in Q4 2025.
- How has Kura Oncology's ROW license — contract with customer liability revenue recognized changed year-over-year?
- Kura Oncology's ROW license — contract with customer liability revenue recognized decreased by 59.0% year-over-year, from $12.45M to $5.1M.
- What does ROW license — contract with customer liability revenue recognized mean?
- This metric represents the amount of revenue recognized during the period that was previously recorded as deferred revenue or a contract liability related to Rest of World (ROW) licensing agreements. It reflects the fulfillment of performance obligations under collaboration or licensing arrangements as the company satisfies its contractual commitments to partners. Tracking this value helps investors understand the pace at which upfront payments or milestone-related liabilities are being converted into recognized revenue over the life of a partnership.
Ask your AI about Kura Oncology's row license — contract with customer liability revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
